Perjeta, formally called pertuzumab, signifies a significant advancement in addressing HER2-positive mammary cancer. The medication works by targeting a specific pathway that helps cancer cells multiply . In contrast to some alternative HER2-targeted therapies, pertuzumab doesn't directly block t